Merck faces heavy competition in almost every area of brain research, especially from Pfizer, which has been working on substance P blockers for depression and on new, safer antianxiety drugs.
But as long as Clinton's diet-substance strategy is working so well, he's not likely to hustle to appropriate Lamm's message, unless anyone seems to be buying it.